Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

Giampaolo Bianchini, Takayuki Iwamoto, Yuan Qi, Charles Coutant, Christine Y. Shiang, Bailang Wang, Libero Santarpia, Vicente Valero, Gabriel N. Hortobagyi, W. Fraser Symmans, Luca Gianni, Lajos Pusztai

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.

Original languageEnglish
Pages (from-to)8852-8862
Number of pages11
JournalCancer Research
Volume70
Issue number21
DOIs
Publication statusPublished - Nov 1 2010

Fingerprint

Phosphotransferases
Breast Neoplasms
Estrogen Receptors
Therapeutics
Mitosis
Neoplasms
human ERBB2 protein
Protein Kinases
Small Interfering RNA
Down-Regulation
Multivariate Analysis
Gene Expression
Drug Therapy
Cell Line
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. / Bianchini, Giampaolo; Iwamoto, Takayuki; Qi, Yuan; Coutant, Charles; Shiang, Christine Y.; Wang, Bailang; Santarpia, Libero; Valero, Vicente; Hortobagyi, Gabriel N.; Symmans, W. Fraser; Gianni, Luca; Pusztai, Lajos.

In: Cancer Research, Vol. 70, No. 21, 01.11.2010, p. 8852-8862.

Research output: Contribution to journalArticle

Bianchini, G, Iwamoto, T, Qi, Y, Coutant, C, Shiang, CY, Wang, B, Santarpia, L, Valero, V, Hortobagyi, GN, Symmans, WF, Gianni, L & Pusztai, L 2010, 'Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer', Cancer Research, vol. 70, no. 21, pp. 8852-8862. https://doi.org/10.1158/0008-5472.CAN-10-1039
Bianchini, Giampaolo ; Iwamoto, Takayuki ; Qi, Yuan ; Coutant, Charles ; Shiang, Christine Y. ; Wang, Bailang ; Santarpia, Libero ; Valero, Vicente ; Hortobagyi, Gabriel N. ; Symmans, W. Fraser ; Gianni, Luca ; Pusztai, Lajos. / Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. In: Cancer Research. 2010 ; Vol. 70, No. 21. pp. 8852-8862.
@article{38ca771b78154b6ea9710992247943f7,
title = "Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer",
abstract = "Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.",
author = "Giampaolo Bianchini and Takayuki Iwamoto and Yuan Qi and Charles Coutant and Shiang, {Christine Y.} and Bailang Wang and Libero Santarpia and Vicente Valero and Hortobagyi, {Gabriel N.} and Symmans, {W. Fraser} and Luca Gianni and Lajos Pusztai",
year = "2010",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-10-1039",
language = "English",
volume = "70",
pages = "8852--8862",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

AU - Bianchini, Giampaolo

AU - Iwamoto, Takayuki

AU - Qi, Yuan

AU - Coutant, Charles

AU - Shiang, Christine Y.

AU - Wang, Bailang

AU - Santarpia, Libero

AU - Valero, Vicente

AU - Hortobagyi, Gabriel N.

AU - Symmans, W. Fraser

AU - Gianni, Luca

AU - Pusztai, Lajos

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.

AB - Different kinases are expressed in different clinical subsets of breast cancer. In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro. Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns. We tested the prognostic value of kinase metagenes in 684 node-negative patients who received no adjuvant therapy and the predictive value in 233 patients who received uniform neoadjuvant chemotherapy. Twelve kinases were overexpressed in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 7 in HER2+, and 28 in ER -/HER2- cancers, respectively. We examined the functional role of 22 kinases overexpressed in ER-/HER2- cancers using siRNA. Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro. Two robust kinase clusters, including an immune kinase cluster and a mitosis kinase cluster, were present in all clinical subgroups. High mitosis kinase score was associated with worse prognosis but higher pathologic complete response (pCR) in ER+/HER2- cancers, but not in ER-/HER2- or HER2+ cancers, in univariate and multivariate analyses including other genomic predictors (MammaPrint, genomic grade index, and the 76-gene signature). Conversely, higher immune kinase score was associated with better survival in ER +/HER2- and HER2+ tumors and also predicted higher probability of pCR in HER2+ cancers. Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.

UR - http://www.scopus.com/inward/record.url?scp=78449290946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449290946&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1039

DO - 10.1158/0008-5472.CAN-10-1039

M3 - Article

C2 - 20959472

AN - SCOPUS:78449290946

VL - 70

SP - 8852

EP - 8862

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -